Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in overall survival compared with biological therapy (moderate certainty).
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemmotherapy combined with biological therapy showed no clear difference in overall survival compared with chemotherapy (moderate certainty).
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations may leads to lower overall survival compared with 5‐FU/anthracycline combinations (without cisplatin) (low certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Irinotecan probably leads to lower overall survival compared with non‐irinotecan‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Docetaxel leads to lower overall survival compared with non‐docetaxel‐containing regimens (high certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Combination probably leads to lower overall survival compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Capecitabine showed no clear difference in overall Survival compared with 5‐FU‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Oxaliplatin may leads to lower overall Survival compared with the same regimen including cisplatin (low certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes overall survival compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
S‐1 showed no clear difference in overall Survival compared with 5‐FU‐containing regimens (high certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations probably leads to lower overall survival compared with 5‐FU/cisplatin combinations (without anthracyclines) (moderate certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Overall survival (OS) · patients with resectable gastric cancer
Post‐surgical chemotherapy leads to lower overall Survival (OS) compared with surgery alone (high certainty).
1 finding from 1 review
Overall survival ‐ Other comparisons · people with advanced gastric cancer
It is very uncertain whether irinotecan changes overall survival ‐ Other comparisons compared with non‐irinotecan‐containing regimens (very low certainty).
1 finding from 1 review
Overall survival ‐ Other comparisons · people with advanced gastric cancer
It is very uncertain whether docetaxel changes overall survival ‐ Other comparisons compared with non‐docetaxel‐containing regimens (very low certainty).
1 finding from 1 review
Overall survival ‐ Additive comparisons · people with advanced gastric cancer
Irinotecan showed no clear difference in overall survival ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (low certainty).
1 finding from 1 review
Overall survival ‐ Additive comparisons · people with advanced gastric cancer
Docetaxel probably leads to lower overall survival ‐ Additive comparisons compared with non‐docetaxel‐containing regimens (moderate certainty).
1 finding from 1 review